Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Conditions
- Acute Lymphoblastic Leukemia
- Chronic Lymphoblastic Leukemia
- B-cell Lymphoma
Interventions
- DRUG: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators